Sign in

CIK 0001806310

  • Non-accelerated filer
  • Smaller reporting company

Taysha Gene Therapies, Inc.

Sign in to watch
Ticker
TSHA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
843199512
Phone
+1 214-612-0000
Business address
3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247
  1. 4 Open-market buy Director bought 10,000 shares at $8.01 ($80,100)
  2. 4 Open-market buy Director bought 3,000 shares at $7.78 ($23,340)
  3. 4 Open-market buy President and CEO bought 42,518 shares at an average $12.44 ($529,102)
  4. 4 Open-market buy Director bought 2,202 shares at $13.19 ($29,044)
  5. 4 Open-market buy Director bought 20,000 shares at $12.54 ($250,800)
  6. 4 Open-market sale Chief Financial Officer sold 33,000 shares at an average $16.88 ($557,023)
  7. 4 Open-market sale CMO and Head of R&D sold 79,000 shares at an average $22.63 ($1,787,936)
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Open-market buy Director bought 1,170 shares at $22.35 ($26,150)
  15. 4 Open-market buy Director bought 12,000 shares at $20.98 ($251,760)
  16. 5 Insider Annual Insider Trading Report
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 5 of 6 · 120 filings